Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Warfarin | 7 | 2023 | 123 | 2.110 |
Why?
|
| Anticoagulants | 10 | 2024 | 598 | 1.830 |
Why?
|
| Percutaneous Coronary Intervention | 5 | 2024 | 298 | 1.610 |
Why?
|
| Pharmacy | 2 | 2022 | 18 | 1.420 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2024 | 268 | 1.340 |
Why?
|
| Cytochrome P-450 CYP2C19 | 5 | 2024 | 26 | 1.290 |
Why?
|
| Cytochrome P-450 CYP2C9 | 2 | 2020 | 6 | 1.190 |
Why?
|
| Genotype | 8 | 2024 | 2588 | 0.980 |
Why?
|
| Pharmacogenetics | 7 | 2025 | 201 | 0.950 |
Why?
|
| Pharmacists | 4 | 2023 | 104 | 0.810 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2021 | 10 | 0.690 |
Why?
|
| Pharmacy Residencies | 1 | 2021 | 6 | 0.690 |
Why?
|
| Pharmacogenomic Variants | 2 | 2020 | 38 | 0.670 |
Why?
|
| Acute Coronary Syndrome | 1 | 2023 | 235 | 0.630 |
Why?
|
| Students, Pharmacy | 1 | 2021 | 76 | 0.620 |
Why?
|
| Learning | 1 | 2022 | 353 | 0.600 |
Why?
|
| Professional Role | 2 | 2017 | 78 | 0.520 |
Why?
|
| Hemorrhage | 6 | 2023 | 485 | 0.470 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 182 | 0.440 |
Why?
|
| Urban Population | 1 | 2017 | 284 | 0.440 |
Why?
|
| Rural Population | 1 | 2017 | 273 | 0.420 |
Why?
|
| Decision Support Systems, Clinical | 3 | 2025 | 203 | 0.370 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 828 | 0.360 |
Why?
|
| Pharmacogenomic Testing | 5 | 2024 | 47 | 0.350 |
Why?
|
| Internship and Residency | 1 | 2021 | 1217 | 0.330 |
Why?
|
| Antithrombins | 2 | 2021 | 49 | 0.280 |
Why?
|
| Precision Medicine | 4 | 2024 | 381 | 0.230 |
Why?
|
| Humans | 24 | 2025 | 130204 | 0.220 |
Why?
|
| Administration, Oral | 3 | 2021 | 706 | 0.200 |
Why?
|
| Patient Readmission | 2 | 2025 | 439 | 0.190 |
Why?
|
| Thromboembolism | 1 | 2023 | 93 | 0.180 |
Why?
|
| Venous Thromboembolism | 2 | 2023 | 191 | 0.180 |
Why?
|
| Universities | 1 | 2022 | 125 | 0.180 |
Why?
|
| Genotyping Techniques | 1 | 2022 | 110 | 0.170 |
Why?
|
| Retrospective Studies | 5 | 2024 | 17577 | 0.170 |
Why?
|
| Vitamin K | 1 | 2021 | 34 | 0.170 |
Why?
|
| Coronary Thrombosis | 1 | 2021 | 35 | 0.170 |
Why?
|
| International Normalized Ratio | 1 | 2020 | 45 | 0.160 |
Why?
|
| Schools | 1 | 2022 | 235 | 0.160 |
Why?
|
| Students | 1 | 2022 | 246 | 0.160 |
Why?
|
| Antidiarrheals | 1 | 2020 | 17 | 0.160 |
Why?
|
| Antacids | 1 | 2020 | 28 | 0.160 |
Why?
|
| Biological Availability | 1 | 2020 | 135 | 0.160 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2019 | 33 | 0.150 |
Why?
|
| Middle Aged | 8 | 2025 | 28315 | 0.140 |
Why?
|
| Gene Frequency | 1 | 2020 | 729 | 0.140 |
Why?
|
| Aged | 6 | 2025 | 20818 | 0.140 |
Why?
|
| Adult | 7 | 2025 | 31035 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 290 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2020 | 401 | 0.130 |
Why?
|
| Medication Reconciliation | 1 | 2017 | 17 | 0.130 |
Why?
|
| Obesity, Morbid | 1 | 2019 | 231 | 0.130 |
Why?
|
| Male | 9 | 2025 | 64425 | 0.120 |
Why?
|
| Professional-Patient Relations | 1 | 2017 | 92 | 0.120 |
Why?
|
| Treatment Outcome | 7 | 2023 | 12824 | 0.120 |
Why?
|
| Genetic Testing | 2 | 2021 | 1104 | 0.120 |
Why?
|
| Thrombosis | 1 | 2020 | 498 | 0.120 |
Why?
|
| Dabigatran | 1 | 2015 | 26 | 0.110 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 231 | 0.110 |
Why?
|
| Female | 8 | 2025 | 70342 | 0.110 |
Why?
|
| Atrial Fibrillation | 2 | 2019 | 736 | 0.110 |
Why?
|
| Electronic Health Records | 2 | 2022 | 834 | 0.100 |
Why?
|
| Text Messaging | 1 | 2014 | 41 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1604 | 0.100 |
Why?
|
| Reminder Systems | 1 | 2014 | 61 | 0.100 |
Why?
|
| Coronary Artery Disease | 1 | 2020 | 890 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2014 | 141 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 6764 | 0.100 |
Why?
|
| Drug Prescriptions | 3 | 2021 | 234 | 0.090 |
Why?
|
| Alleles | 1 | 2017 | 1674 | 0.090 |
Why?
|
| Hypertension | 1 | 2020 | 1352 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 4036 | 0.080 |
Why?
|
| Young Adult | 3 | 2025 | 10000 | 0.080 |
Why?
|
| Hospitalization | 2 | 2023 | 1939 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2025 | 6407 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2C19 Inhibitors | 1 | 2022 | 2 | 0.050 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2022 | 43 | 0.050 |
Why?
|
| Mandatory Programs | 1 | 2022 | 6 | 0.040 |
Why?
|
| Physicians | 2 | 2022 | 626 | 0.040 |
Why?
|
| Inpatients | 1 | 2025 | 558 | 0.040 |
Why?
|
| Phenotype | 2 | 2020 | 4454 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1613 | 0.040 |
Why?
|
| Enoxaparin | 1 | 2015 | 42 | 0.030 |
Why?
|
| Rivaroxaban | 1 | 2015 | 49 | 0.030 |
Why?
|
| Thiazoles | 1 | 2015 | 113 | 0.030 |
Why?
|
| Prothrombin Time | 1 | 2014 | 36 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2014 | 21 | 0.030 |
Why?
|
| Pyridones | 1 | 2015 | 139 | 0.030 |
Why?
|
| Automation | 1 | 2014 | 65 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 407 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 109 | 0.030 |
Why?
|
| Pyridines | 1 | 2015 | 256 | 0.030 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2015 | 151 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2015 | 350 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 3679 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2014 | 291 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 1119 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6166 | 0.020 |
Why?
|
| Patient Safety | 1 | 2014 | 444 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 700 | 0.020 |
Why?
|
| Stroke | 1 | 2015 | 1059 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 10967 | 0.010 |
Why?
|
| United States | 1 | 2020 | 11959 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 2108 | 0.010 |
Why?
|